KIT受体及其配体干细胞因子在默克尔细胞癌中的共表达。
Co-expression of KIT receptor and its ligand stem cell factor in Merkel cell carcinoma.
作者信息
Krasagakis Konstantin, Kruger-Krasagakis Sabine, Eberle Jürgen, Tsatsakis Aristidis, Tosca Androniki D, Stathopoulos Efstathios N
机构信息
Department of Dermatology, Faculty of Medicine, University of Crete, Heraklion, Greece.
出版信息
Dermatology. 2009;218(1):37-43. doi: 10.1159/000173704. Epub 2008 Nov 12.
BACKGROUND/AIMS: KIT receptor has been implicated in the pathogenesis of cancer, either by mutation or autocrine activation. Merkel cell carcinoma (MCC) is a rare KIT-positive cutaneous tumor. We investigated the co-expression of KIT and its ligand stem cell factor (SCF) in MCC.
METHODS
Sixteen specimens from 13 MCC patients of various tumor stages were examined by immunohistochemistry for SCF, KIT, Ki67/MIB-1 and cleaved caspase 3 expression, and for apoptosis by TUNEL.
RESULTS
KIT was expressed in 13 of 16 tumors, and SCF in 15 of 16 specimens. Co-expression of KIT and SCF was detected in 12 of 16 tumors. KIT and SCF immunoreactivity scores were independent of tumor stage. Ki67/MIB-1 proliferation rates were high, whereas apoptosis rates were low, and did not depend on KIT or SCF expression.
CONCLUSION
Co-expression of KIT and SCF in a high percentage of MCC tumors hints to an autocrine mechanism. KIT and SCF expression in primary tumors and in metastases suggests an early event in Merkel cell transformation.
背景/目的：KIT受体通过突变或自分泌激活参与癌症的发病机制。默克尔细胞癌（MCC）是一种罕见的KIT阳性皮肤肿瘤。我们研究了KIT及其配体干细胞因子（SCF）在MCC中的共表达情况。
方法
对13例不同肿瘤分期的MCC患者的16个标本进行免疫组织化学检查，以检测SCF、KIT、Ki67/MIB-1和裂解的半胱天冬酶3的表达，并通过TUNEL检测细胞凋亡情况。
结果
16个肿瘤中有13个表达KIT，16个标本中有15个表达SCF。16个肿瘤中有12个检测到KIT和SCF的共表达。KIT和SCF免疫反应评分与肿瘤分期无关。Ki67/MIB-1增殖率高，而凋亡率低，且与KIT或SCF表达无关。
结论
高比例的MCC肿瘤中KIT和SCF的共表达提示存在自分泌机制。原发性肿瘤和转移灶中KIT和SCF的表达表明默克尔细胞转化过程中存在早期事件。
Zotero 插件